EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current State of Molecular Cytology in Thyroid Nodules: Platforms and Their Diagnostic and Theranostic Utility

Zeina C Hannoush iD, Roberto Ruiz-Cordero, Mark Jara, Atil Y Kargi

Journal of Clinical Medicine · 19.03.2024 · 13 (6) · 1759

DOI: 10.3390/jcm13061759 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.03.2024. Verfasst von Zeina C Hannoush und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136,…. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The high prevalence of thyroid nodules and increased availability of neck ultrasound have led to an increased incidence of diagnostic thyroid fine needle aspirations, with approximately 20% yielding indeterminate results. The recent availability of molecular tests has helped guide the clinical management of these cases. This paper aims to review and compare three main commercially available molecular cytology platforms in the U.S.—Afirma GSC, Thyroseq GC, and ThyGeNEXT + ThyraMIR. Sequential improvements of the Afirma GSC and Thyroseq GC tests have increased positive and negative predictive values, sensitivity, and specificity. Comparative studies revealed similar diagnostic performance between these tests, with considerations for factors such as cost and processing time. Thyroseq GC provides detailed genomic information and specific management recommendations. ThyGeNEXT + ThyraMIR, though less studied, presents promising results, particularly in miRNA analysis for weak driver mutations. Challenges in interpreting results include variations in reporting and the evolving nature of testing platforms. Questions persist regarding cost-effectiveness and the utility of ultrasound characteristics in selecting candidates for molecular testing. While molecular testing has primarily served diagnostic purposes, advancements in understanding genetic alterations now offer therapeutic implications. FDA-approved options target specific genetic alterations, signaling a promising future for tailored treatments.

Schlagwörter

Stichwörter der Autor:innen

fine needle aspirationgenetic analysismolecular cytologymutationthyroid cancerthyroid nodule

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
  • Department of Pathology and Laboratory Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
  • Department of Neurosurgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

ORCID-Profile: Zeina C Hannoush

Zitieren

APA

Hannoush, Z. C., Ruiz-Cordero, R., Jara, M., & Kargi, A. Y. (2024). Current State of Molecular Cytology in Thyroid Nodules: Platforms and Their Diagnostic and Theranostic Utility. Journal of Clinical Medicine, 13(6), 1759. https://doi.org/10.3390/jcm13061759

Vancouver

Hannoush ZC, Ruiz-Cordero R, Jara M, Kargi AY. Current State of Molecular Cytology in Thyroid Nodules: Platforms and Their Diagnostic and Theranostic Utility. Journal of Clinical Medicine. 2024;13(6):1759. doi:10.3390/jcm13061759

BibTeX
@article{Hannoush2024,
  author = {Hannoush, Zeina C and Ruiz-Cordero, Roberto and Jara, Mark and Kargi, Atil Y},
  title = {Current State of Molecular Cytology in Thyroid Nodules: Platforms and Their Diagnostic and Theranostic Utility},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {6},
  pages = {1759},
  doi = {10.3390/jcm13061759}
}
Kostenlos starten →